iShares Nasdaq Biotechnology Index Fund (IBB) : Fridays money flow points at investors jumping to buy the stock on the weakness of price. $83.11 million worth of transactions were on upticks, whereas, the downticks accounted for $81.53 million worth of transactions. The net money flow was a positive $1.58 million and the uptick to downtick ratio was 1.02. The net money flow into the stock was $0 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $0 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. iShares Nasdaq Biotechnology Index Fund (IBB) was trading at $280.61, down $0.83 during day. The stock slid -0.29% over the previous days close. For the week, the stock recorded -1.59% over the previous weeks close.
Institutional Investors own 54.18% of iShares Nasdaq Biotechnology Index Fund shares.
iShares Nasdaq Biotechnology Index Fund (IBB) : During the past 4 weeks, traders have been relatively bearish on iShares Nasdaq Biotechnology Index Fund (IBB), hence the stock is down -5.49% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.08% relative to the S&P 500. The 4-week change in the price of the stock is -5.61% and the stock has fallen -1.59% in the past 1 week.
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Funds investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.